MedTrace Logo

Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS

NCT00505401 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2011-03-01

No results posted yet for this study

Summary

The development of a vaccine against HIV/AIDS has been primary focused on the structural proteins (Env, Gag) of HIV-1 with the aim of inducing sterilizing immunity by blocking virus entry. Alternative approaches are focused on new vaccine strategies aimed at modifying the virus-host dynamic favouring the establishment of a long-term non-progressing disease status. Such strategies target regulatory proteins that are the first to be expressed after infection and are essential for viral replication, infectivity and pathogenesis. Thus, this approach may be effective for both preventive and therapeutic vaccination strategies.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

recombinant HIV-1 Tat protein

Sponsors & Collaborators

  • Istituto Superiore di Sanità

    lead OTHER

Principal Investigators

  • Barbara Ensoli, MD, PhD · National AIDS Center, Istituto Superiore di Sanità, Rome, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Completion
2007-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505401 on ClinicalTrials.gov